FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 161 filers reported holding FATE THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $236,791 | +40.3% | 110,392 | +212.3% | 0.00% | – |
| Q2 2023 | $168,811 | -29.7% | 35,353 | -16.6% | 0.00% | – |
| Q1 2023 | $240,241 | -45.2% | 42,408 | -3.2% | 0.00% | -100.0% |
| Q4 2022 | $438,420 | -24.1% | 43,798 | +74.5% | 0.00% | 0.0% |
| Q3 2022 | $578,000 | +124.0% | 25,097 | +139.6% | 0.00% | – |
| Q2 2022 | $258,000 | -22.1% | 10,474 | +25.6% | 0.00% | – |
| Q1 2022 | $331,000 | -10.1% | 8,341 | +97.5% | 0.00% | – |
| Q2 2021 | $368,000 | -26.7% | 4,223 | -65.9% | 0.00% | -100.0% |
| Q3 2020 | $502,000 | -7.7% | 12,391 | -21.8% | 0.00% | 0.0% |
| Q2 2020 | $544,000 | +133.5% | 15,852 | +54.2% | 0.00% | 0.0% |
| Q1 2020 | $233,000 | – | 10,279 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $200,277,000 | 17.57% |
| Redmile Group, LLC | 12,957,222 | $767,975,000 | 13.39% |
| Copernicus Capital Management, LLC | 12,000 | $711,000 | 8.60% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $61,478,000 | 7.53% |
| DAFNA Capital Management LLC | 344,360 | $20,410,000 | 5.42% |
| Casdin Capital, LLC | 3,400,000 | $201,518,000 | 5.02% |
| Ally Bridge Group (NY) LLC | 270,000 | $16,003,000 | 4.70% |
| Darwin Global Management, Ltd. | 353,250 | $20,937,000 | 3.85% |
| Bellevue Group AG | 3,238,036 | $191,918,000 | 1.95% |
| Artal Group S.A. | 1,450,000 | $85,942,000 | 1.92% |